Advances in therapy for chronic hepatitis B.

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Current treatments for chronic hepatitis B, interferon alfa and lamivudine, have limitations including low efficacy, side effects, and drug resistance.
• A significant unmet need exists for safe and effective therapies for a large proportion of chronic hepatitis B patients.

Purpose of the Study:

• To analyze the safety and efficacy of adefovir dipivoxil, a new nucleotide analogue, in diverse chronic hepatitis B patient populations.
• To evaluate adefovir dipivoxil's performance in HBeAg-positive and HBeAg-negative patients, including those with lamivudine resistance and HIV coinfection.

Main Methods:

• Integrated analysis of emerging data from recent studies on adefovir dipivoxil.
• Inclusion of patient groups with HBeAg-positive/negative chronic hepatitis B, lamivudine-resistant disease, HIV coinfection, and pre/posttransplant decompensated liver disease.

Main Results:

• Adefovir dipivoxil 10 mg/d demonstrated potent anti-hepatitis B virus (HBV) activity across all studied patient populations.
• The drug was well-tolerated with minimal adverse effects, showing rapid and sustained virological, serological, histological, and biochemical responses.
• Significant histological improvement was observed in all patient subgroups at 48 weeks.

Conclusions:

• Adefovir dipivoxil is a safe and efficacious treatment option for chronic hepatitis B, including difficult-to-treat populations.
• The nucleotide analogue adefovir dipivoxil provides consistent and broad-spectrum anti-HBV activity with a favorable safety profile.